Survival

GKIDA Launches Ultra-Light Portable Emergency Kit for Daily Living and Travel Safety

Retrieved on: 
Wednesday, October 25, 2023
Retail, Health, Other Retail, Other Travel, Other Health, Travel, Survival, Emergency, Prevalence, Disaster, Medicine, Risk, Korea Meteorological Administration, Fire, Bottled water

GKIDA , a disaster and safety supplies company, has launched an ultra-light portable emergency kit.

Key Points: 
  • GKIDA , a disaster and safety supplies company, has launched an ultra-light portable emergency kit.
  • GKIDA's ultra-light portable emergency kit weighs only 100 grams and includes first aid medicine, a raincoat, a lantern, a glow stick, and a whistle.
  • In contrast, the GKIDA's portable survival and relief kit won the 2022 Good Design Award for both its remarkable design and survival functionality.
  • To learn more about the GKIDA Ultra-Light Portable Emergency Kit, please visit the website: https://gkida.com/
    View source version on businesswire.com: https://www.businesswire.com/news/home/20231025991052/en/

Global Platform Study Presents Results to Guide Care of Severely Ill Patients With COVID-19 Using Routinely Available Drugs – Simvastatin and Vitamin C

Retrieved on: 
Wednesday, October 25, 2023
Science, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Hospitals, Clinical Trials, WHO, Urinary tract infection, Survival, FRCP, Patient, Vitamin C, Simvastatin, Royal Victoria Hospital, Montreal, Bronchopneumonia, MPH, Global Coalition Against Pneumonia, Oregon Health & Science University, University, Respiratory tract infection, JAMA, Professor, Vitamin, Multimedia, Queen's University Belfast, University of Pittsburgh School of Medicine, Learning, Critical Care Medicine (journal), COVID, Clinical trial, Intensive care unit, Hospital, NEJM, Probability, Pittsburgh, European Society of Clinical Microbiology and Infectious Diseases, Wilfrid Sellars, SUNY Downstate Health Sciences University, Hospice and palliative medicine, Intensive care medicine, Royal Victoria Hospital, UPMC, Consultant, Ohio State University Wexner Medical Center, Pharmaceutical industry, Dietary supplement, MD

Vitamin C is widely available around the world and was used in some settings for the treatment of COVID-19.

Key Points: 
  • Vitamin C is widely available around the world and was used in some settings for the treatment of COVID-19.
  • Through harmonizing two clinical trials – REMAP-CAP and LOVIT-COVID – over 2500 patients in 20 countries took part, including both critically ill and non-critically ill patients with COVID-19 in hospital.
  • It was shown that high dose vitamin C did not improve outcomes for patients.
  • Intravenous Vitamin C for Patients Hospitalized with COVID-19: Two Harmonized Randomized Clinical Trials.

Planview Makes Disconnected Roadmap Tools Obsolete

Retrieved on: 
Wednesday, October 25, 2023
Other Professional Services, Software, Data Analytics, Artificial Intelligence, Data Management, Professional Services, Technology, Business, Knowledge, Survival, Information silo, Connective tissue, Work, Organization, Methodology, Blue Shield, Management, Risk management, Sales, Planview

Planview , a global leader in Portfolio and Value Stream Management, today announced Planview Roadmaps.

Key Points: 
  • Planview , a global leader in Portfolio and Value Stream Management, today announced Planview Roadmaps.
  • "Planview Roadmaps acts as the connective tissue between strategy and work, connecting every team with unprecedented visualization across the business.
  • Planview Roadmaps enable organizations to see and adapt to change by visually organizing work in one connected view.
  • With Planview Roadmaps, teams can connect strategy with outcomes and team milestones, mapping work to critical outcomes and ensure progress on most critical initiatives.

Embark on a New Adventure to Reclaim the Lost Kingdom of Khazad-dûm in The Lord of the Rings: Return to Moria™, Available Now on PC

Retrieved on: 
Tuesday, October 24, 2023
Technology, Electronic Games, Men, Retail, Social Media, Entertainment, Family, Consumer, Online Retail, General Entertainment, Teens, Communications, Internet, Consumer Electronics, Gimli, Dark, Mithril, Survival, Gold, Performance-based building design, Cooperative, Quartz, Mining, Morale, Temperature, Food, PEGI, Weapon, Architecture, MSRP, Geography of Middle-earth, Fellow, Darkness, Multimedia, Friends, Environment, Ring, Mine, Arachnoid, Lord, Shadow, Craft, Sleep, ESRB, Discord, Safety, Xbox Series X and Series S, Book, History of Arda, Moria, Middle-earth, Epic Games Store, Console, Iron, Video game, Film industry, Dwarf, Moria

We've stuffed it with as much lore, exploration, danger and joy as we could fit,” said Jon-Paul Dumont, Game Director, Free Range Games.

Key Points: 
  • We've stuffed it with as much lore, exploration, danger and joy as we could fit,” said Jon-Paul Dumont, Game Director, Free Range Games.
  • With the support of our incredible community, this is just the start of our adventures in Khazad-dûm."
  • John Rhys-Davies Voices Lord Gimli Lockbearer: Venerable actor John Rhys-Davies reprises his iconic role of Lord Gimli Lockbearer, leading the game’s official voice actor’s cast.
  • The game is currently scheduled for release on PlayStation®5 on Dec. 5, 2023, and Xbox Series X|S in early 2024.

Canadian Coast Guard's Arctic Marine Response Station in Rankin Inlet, Nunavut completes operational season

Retrieved on: 
Wednesday, October 25, 2023
Survival, Government, Canadian Coast Guard, Radio, Canadian Coast Guard Auxiliary, Exercise, Environment, Joint Rescue Coordination Centre Victoria, Indigenous peoples, VHF, Joint Rescue Coordination Centre, VHF radio, Whaling, NT, Arctic

YELLOWKNIFE, NT, Oct. 25, 2023 /CNW/ - The Canadian Coast Guard's Arctic Marine Response Station (AMRS) in Rankin Inlet, Nunavut has wrapped up its operational season, closing on October 25, 2023.

Key Points: 
  • YELLOWKNIFE, NT, Oct. 25, 2023 /CNW/ - The Canadian Coast Guard's Arctic Marine Response Station (AMRS) in Rankin Inlet, Nunavut has wrapped up its operational season, closing on October 25, 2023.
  • AMRS crews work closely with the Canadian Coast Guard Auxiliary, Inuit communities, and other northern organizations and partner agencies to increase maritime safety in the Arctic.
  • The Arctic Marine Response Station, formerly known as the Inshore Rescue Boat North station, first opened in 2018, establishing it as the first Canadian Coast Guard search and rescue facility in the Arctic.
  • The station is crewed by Indigenous People, hired and trained by the Canadian Coast Guard.

Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer

Retrieved on: 
Wednesday, October 25, 2023
CR, Response evaluation criteria in solid tumors, Bevacizumab, Survival, Patient, PD-L1, Carboplatin, New Drug Application, Cervical cancer, Incidence, ESMO, Progression-free survival, Trae tha Truth, Center for Drug Evaluation and Research, DOR, DCR, Squamous-cell carcinoma, Cisplatin, The New England Journal of Medicine, Neoplasm, Treatment, European Society for Medical Oncology, PFS, PD-1, American Society of Clinical Oncology, HIV disease progression rates, CC, Chinese, CPS, Paclitaxel, Immunotherapy, CDE, Diagnosis, Oncology, ORR, Anemia, RECIST, NDA, Safety, Ira Pastan, OS, Toxicity, Cohort, Performance, CI, Pharmaceutical industry, Medical imaging

This trial studied the use of QL1706 (iparomlimab and tuvonralimab) in combination with chemotherapy, with or without bevacizumab, as a first-line treatment of recurrent or metastatic cervical cancer (r/mCC).

Key Points: 
  • This trial studied the use of QL1706 (iparomlimab and tuvonralimab) in combination with chemotherapy, with or without bevacizumab, as a first-line treatment of recurrent or metastatic cervical cancer (r/mCC).
  • Moreover, the treatment exhibited a manageable safety profile without any new safety signals observed, making it a potential new first-line treatment option for r/mCC patients.
  • Currently, the preferred standard first-line treatment for r/mCC patients is cisplatin or carboplatin and paclitaxel plus bevacizumab, and efficacy and safety of the treatment also need to be considered.
  • For r/mCC patients with positive PD-L1 expression, the PD-1 inhibitor pembrolizumab, administered with chemotherapy and with or without bevacizumab, is recommended as the standard first-line treatment.

Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer

Retrieved on: 
Wednesday, October 25, 2023
CR, Response evaluation criteria in solid tumors, Bevacizumab, Survival, Patient, PD-L1, Carboplatin, New Drug Application, Cervical cancer, Incidence, ESMO, Progression-free survival, Trae tha Truth, Center for Drug Evaluation and Research, DOR, DCR, Squamous-cell carcinoma, Cisplatin, The New England Journal of Medicine, Neoplasm, Treatment, European Society for Medical Oncology, PFS, PD-1, American Society of Clinical Oncology, HIV disease progression rates, CC, Chinese, Multimedia, CPS, Paclitaxel, Immunotherapy, CDE, Diagnosis, Oncology, ORR, Anemia, RECIST, NDA, Safety, Ira Pastan, OS, Toxicity, Cohort, Performance, CI, Pharmaceutical industry, Medical imaging

This trial studied the use of QL1706 (iparomlimab and tuvonralimab) in combination with chemotherapy, with or without bevacizumab, as a first-line treatment of recurrent or metastatic cervical cancer (r/mCC).

Key Points: 
  • This trial studied the use of QL1706 (iparomlimab and tuvonralimab) in combination with chemotherapy, with or without bevacizumab, as a first-line treatment of recurrent or metastatic cervical cancer (r/mCC).
  • Moreover, the treatment exhibited a manageable safety profile without any new safety signals observed, making it a potential new first-line treatment option for r/mCC patients.
  • Currently, the preferred standard first-line treatment for r/mCC patients is cisplatin or carboplatin and paclitaxel plus bevacizumab, and efficacy and safety of the treatment also need to be considered.
  • For r/mCC patients with positive PD-L1 expression, the PD-1 inhibitor pembrolizumab, administered with chemotherapy and with or without bevacizumab, is recommended as the standard first-line treatment.

First Emperor Penguin Chick in Over a Decade Hatched at SeaWorld San Diego; Only Place in Western Hemisphere to See These Threatened Species

Retrieved on: 
Wednesday, October 25, 2023
Endangered Species Act of 1973, Survival, Moulting, Penguin International RFC, Face, News, Organization, Endangered species, Personality, Emperor, Learning, Breeding, Animal, SAN, Climate change, Publishing, Antarctica, SeaWorld, SeaWorld San Diego, Antarctic

SAN DIEGO, Oct. 25, 2023 /PRNewswire/ -- On September 12, 2023, an Emperor penguin chick was hatched for the first time since 2010 at SeaWorld San Diego.

Key Points: 
  • SAN DIEGO, Oct. 25, 2023 /PRNewswire/ -- On September 12, 2023, an Emperor penguin chick was hatched for the first time since 2010 at SeaWorld San Diego.
  • SeaWorld San Diego is the only place on the Western Hemisphere where Emperor penguins can be found, making the hatching a rare and celebratory event.
  • A recent scientific study found a record low for Antarctic sea ice coverage that is adversely impacting Emperor penguin populations.
  • SeaWorld San Diego is the only place in the western hemisphere outside of Antarctica where people can see Emperor penguins.

New Report Reveals Why Ecommerce Thrives While Traditional Retail Struggles

Retrieved on: 
Wednesday, October 25, 2023
Digital, Survival, WooCommerce, Luigi, E-commerce, Commerce, Habit, Organization, Consumer, WordPress, Creative, Chapter 11, Title 11, United States Code, Online shopping, Retail, Magento

ATLANTA, Oct. 25, 2023 /PRNewswire/ -- Nexcess, the premium hosting provider optimized for WordPress, WooCommerce, and Magento, released a report today on economic shifts and their impact on the dwindling traditional commerce sector. The report uncovers the reasons behind stunted traditional commerce growth, strategies for future-proofing through digital transformation, and the steps brick-and-mortar retailers can take to survive.

Key Points: 
  • The report uncovers the reasons behind stunted traditional commerce growth, strategies for future-proofing through digital transformation, and the steps brick-and-mortar retailers can take to survive.
  • Ecommerce sales grew 7.7% compared with a 0.5% increase for overall retail sales from Q2 2022 to Q2 2023.
  • Meanwhile, ecommerce sales have grown rapidly: ecommerce sales grew 7.7% compared with a 0.5% increase for overall retail sales from Q2 2022 to Q2 2023.
  • As online purchases continue to grow and overall retail sales remain largely stagnant, it poses a challenge to the traditional commerce sector.

Visgenx Announces Issuance of a U.S. Patent Claiming Compositions of Candidate ELOVL2 Gene Therapy

Retrieved on: 
Wednesday, October 25, 2023
Survival, Ageing, Patent, Therapy, AMD, Pancreas, Liver, Entrepreneurship, Cell, Tissue, Methylation, Research and development, Brain, 1836 U.S. Patent Office fire, Retina, SAN, Fine chemical, Pharmaceutical industry, Research

SAN DIEGO, Oct. 25, 2023 /PRNewswire/ -- Visgenx, Inc., a biotechnology company focused on developing gene therapies for degenerative retinal diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,793,890, entitled "ELOVL2 Constructs for Human Gene Therapy". The patent, which is exclusively owned by Visgenx, has an expiration date of October 19, 2041.   

Key Points: 
  • 11,793,890, entitled "ELOVL2 Constructs for Human Gene Therapy".
  • The patent, which is exclusively owned by Visgenx, has an expiration date of October 19, 2041.
  • Accordingly, we believe that ELOVL2 gene therapy is an attractive strategy for treating these conditions."
  • "The issued patent covers an optimized ELOVL2 transgene that can be used in expression vectors targeting multiple tissues," said Chris Chavez, Ph.D., Vice President of Research and Development at Visgenx and primary inventor on the patent.